Ganja
Ubat Kencing manis
Studies Show Cannabis Benefits for
Diabetes
Despite the
traditional profiling of pot users’ getting the munchies and gorging on sweets
and junk food, there have been three studies from 2011 to 2016 that disprove
the expected results of obesity from cannabis munchies. Instead, it helps
reduce obesity, prevents diabetes, and resolves pre-diabetes or insulin
resistance.
The two
cannabinoids of the over 80 discovered in cannabis that have major impacts on
areas that surround diabetes are CBD (cannabidiol), which does not have a
psychoactive effect, and THCV, slightly different than THC, but it also does
not produce psychoactive effects.
Here are
those three studies:
1) The study Obesity and
Cannabis Use: Results From 2 Representative National Surveys was published
in 2011 in the American Journal of Epidemiology. The purpose
was to determine if the propensity toward satisfying marijuana users’ munchies
was a factor in obesity.
After
comparing BMI measurements between pot smokers and non-users, the authors concluded
that the “prevalence of obesity is lower in cannabis users than in
nonusers.”
2) The 2013 study Impact of
Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults utilized
4,657 men and women surveyed in the National Health and Nutrition Examination
Survey from 2005 to 2010. Marijuana use was determined discreetly, and
statistical adjustments were made according to use for this study.
After
determining homeostasis model assessment of insulin resistance (HOMA-IR)
from fasting blood samples, the researchers discovered:
Current
marijuana use was associated with 16% lower fasting insulin and 17% lower
HOMA-IR. We found significant associations between marijuana use and smaller
waist circumferences. We found that marijuana use was associated with lower
levels of fasting insulin and HOMA-IR, and smaller waist circumference. (Source abstract)
3) Here’s the human study that isolated
the THCV factor’s effect on diabetes, Efficacy and Safety of
Cannabidiol and Tetrahydrocannabivarin [THCV]on Glycemic and Lipid
Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind,
Placebo-Controlled, Parallel Group Pilot Study.
The study, published 2016 in the American
Diabetes Association’s journal, Diabetes Care, combined 62
subjects with type 2 diabetes randomized to five treatment methods:
CBD
(100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5
mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily),
or matched placebo for 13 weeks.
Compared with
placebo, THCV significantly decreased fasting plasma glucose (…) although
plasma HDL was unaffected. Compared with baseline (but not placebo), CBD
decreased resistin … and increased
glucose-dependent insulinotropic peptide… None of the combination treatments
had a significant impact on endpoints. CBD and THCV were well tolerated.
THCV could represent
a new therapeutic agent in glycemic control in subjects with type 2
diabetes. (Source abstract)
These
studies widen the medical applications of cannabis to include prediabetes and
diabetes 2, as long as the right strains, high in CBD and/or THCV, are chosen.
That’s where consulting a cannabis health practitioner, someone with knowledge
in the cannabis industry, is needed.
.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.